acquired immunodeficiency syndrome; cardiac dysfunction; echocardiogram; oxidative stress; transmission electron microscopy CARDIOMYOPATHY (CM) is an important cardiac complication in acquired immunodeficiency syndrome (AIDS) (4, 6) . Postulated etiologies of AIDS CM include direct human immunodeficiency virus (HIV) infection of the heart (4, 19, 32) after myocarditis (26) , toxicity of AIDS therapeutics (11, 29, 31) , effects of alcohol or drugs (34) , cytokine effects on cardiac performance (5) , and comorbid conditions (3) . More than one cause may be operative in the same patient (reviewed in Refs. 27, 28) .
HIV Tat serves as a transactivator that stimulates transcription and is required for efficient HIV replication (reviewed in Ref. 17) . Tat can activate heterologous promoters and mediate activities of cellular functions. Extracellular Tat promotes growth of spindle cells derived from Kaposi's sarcoma and normal vascular cells (2, 15) . Tat contributes to the activation of endothelial cells and the expression of endothelial cell adhesion molecules (12, 20) .
HIV has been demonstrated in cardiac myocytes in AIDS (4, 19, 32) . However, the cardiac effects of Tat are poorly understood. Tat may impact on drug toxicity and cause oxidative damage in organs and has been shown to decrease glutathione (GSH) content in livers of transgenic mice (TG) (9) . In light of these effects, our working hypothesis states that Tat impacts directly on myocardial cellular function in AIDS patients and contributes to AIDS CM. Experiments in the present study explored the effect of Tat on the structure and function of the cardiac myocyte and of the heart. Previously, HIV Tat was ubiquitously and nonspecifically expressed in TG with various promoters (e.g., ␤-actin promoter) (7-10, 18, 25, 35, 40) . However, those TG models examined Tat effects in noncardiac tissues, lacked tissue targeting, exhibited no Tat myocardial expression, or exhibited Tat expression in multiple tissues without examining cardiac effects. Accordingly, cardiac effects (if any) from ubiquitous TG expression of Tat could result from systemic, local, or combined effects of Tat expression.
Experiments here targeted expression of Tat to cardiac myocytes and focused on changes in myocytic and cardiac structure and function that resulted from Tat expression. An established TG strategy (33, 37) was used to specifically target HIV Tat to murine cardiac myocytes. Selective expression of HIV Tat in the myo-cardium increased left ventricular (LV) mass, decreased ventricular fractional shortening (FS), caused mitochondrial destruction, altered ventricular expression of fetal gene products, and resulted in selective depletion of cardiac GSH. These TG effects worsened over time, and oxidative stress may be a central subcellular event. The data indicate that Tat depressed cardiac contractility in TGs and could contribute to AIDS CM in patients.
EXPERIMENTAL PROCEDURES
Generation of ␣-myosin heavy chain/Tat TGs. Established methods were used. A 1.304-kb HindIII-SmaI fragment containing both exons of Tat (86-residue polypeptide) and an intron from the rat preproinsulin gene (ppI) was isolated from clone pBC12/CMV/Tat-1 (a generous gift from Andrew P. Rice, Univ. of Texas Southwestern Medical Center, Dallas, TX). The fragment was modified with Klenow enzyme (Boehringer, Mannheim, Germany) to fill in the HindIII site. The ␣-myosin heavy chain (␣-MyHC) clone 26 (compliments of Jeff Robins, Children's Research Foundation, Cincinnati, OH; Ref. 39 ) was digested with SalI and then modified with Klenow enzyme followed by treatment with shrimp alkaline phosphatase (Boehringer) to facilitate construction of the final vector. Restriction analysis and DNA sequencing verified the final construct, denoted ␣-MyHC/Tat. To generate TGs, a 7.4-kb NotI-NotI fragment containing the full transcriptional unit was purified and microinjected into FVB one-cell embryos (Charles River, Wilmington, MA). Embryos were implanted into pseudopregnant CD-1 females (Taconic, Germantown, NY). The resulting offspring were screened for incorporation of the transgene. One high-expression hemizygous ( ϩ/Ϫ Tathigh) and two low-expression hemizygous ( ϩ/Ϫ TatlowA,B) TG lines were created. All mice were housed according to National Institutes of Health guidelines and fed ad libitum.
Genotyping. The ␣-MyHC/Tat transgene was detected in the founders and their offspring with Southern blotting and PCR. For Southern blotting, 10 g of mouse genomic tail DNA was digested overnight at 37°C. The digested DNA was subjected to electrophoresis in a 0.7% agarose gel and transferred to a positively charged nylon membrane (Boehringer) overnight. Hybridization was performed in a solution containing 6ϫ SSC (1ϫ SSC: 150 mmol/l NaCl, 15 mmol/l Na citrate), 1% SDS, 10% dextran sulfate, 100 g/ml salmon sperm DNA, and 32 P-labeled Tat cDNA at 68°C overnight. The membranes were then washed once in 2ϫ SSC-1% SDS at room temperature for 15 min and twice in 0.1ϫ SSC-0.1% SDS at 68°C for 30 min and exposed to a storage phosphor screen (Packard Instrument, Meriden, CT). Detection was performed on a Cyclone storage phosphor system (Packard Instrument). Genotyping of the progeny from the founders was accomplished by PCR. Fifty nanograms of mouse genomic tail DNA was used along with primers TAT1 (5ЈGGAGCCAGTAGATCCTAGACTAGAGCC-3Ј) and TAT2 (5ЈCCTCCACCCAGCTCCAGTTGTGC-3Ј), which were designed to detect the presence of the targeted TG. They produced a product of 1.1 kb. PCR was preformed in a 20-l volume with Taq DNA polymerase (Boehringer) in a PTC100 thermal cycler (MJ Research, Watertown, MA) with the following conditions: 5 min at 95°C, followed by 30 cycles of 30 s at 95°C, 30 s at 55°C, 1 min at 72°C, ending with a 3-min extension at 72°C and then 4°C.
RNA extraction and Northern blot analysis. Methods resembled those used by us previously (30) . Total RNA was extracted from tissues of 60-day-old mice with TRI reagent (Molecular Research, Cincinnati, OH). RNA (10 g) was subjected to electrophoresis with the NorthernMax kit (Ambion, Austin, TX) in a 1% agarose gel and transferred to a positively charged nylon membrane enzyme (Boehringer) overnight. Hybridization was performed in ULTRAhyb (Ambion) containing either 32 P-labeled Tat cDNA or 32 P-labeled glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA transcripts at 42°C overnight. The membranes were then washed twice in 2ϫ SSC-0.1% SDS at 42°for 5 min and twice in 0.1ϫ SSC-0.1% SDS at 42°for 15 min and exposed to a storage phosphor screen (Packard Instrument). Detection was preformed on a Cyclone storage phosphor system (Packard Instrument). mRNA was isolated from total RNA samples with the Poly(A) Pure kit (Ambion). Two micrograms of mRNA was subjected to electrophoresis as above and hybridized with probes for TAT and GAPDH.
Cardiac mRNA analysis of ϩ/Ϫ TGhigh and wild-type littermates at 180 days. Total RNA was isolated from LV tissue samples from 60-and 180-day wild-type (WT) and ϩ/Ϫ Tathigh littermates (n ϭ 3 per cohort) by established methods (14, 30) . Northern blots were probed with 32 P-labeled cDNA probes specific for atrial natriuretic factor (ANF; 0.8-kb cDNA fragment of rat ANF courtesy of T. Inagama, Vanderbilt University, Nashville, TN) and specific for sarco(endo)-plasmic reticulum Ca 2ϩ -ATPase (SERCA2; 2.3-kb cDNA fragment of the rat cardiac SERCA2 provided by Dr. W. Dillmann, University of California at San Diego). Equal loading and uniformity of transfer were insured by normalizing hybridization signal intensity to that of GAPDH mRNA. cDNA probes were radiolabeled and hybridized as previously described (14) . The amount of each respective mRNA relative to the amount of GAPDH mRNA was quantified by autoradiography at Ϫ80°C, and signals were quantitatively analyzed by a Packard Instrument Cyclone storage phosphor system.
Protein extraction and Western blot analysis. Total protein was isolated from 60-day WT, ϩ/Ϫ Tathigh, and ϩ/Ϫ TatlowA hearts with T-PER tissue protein extraction reagent (Pierce, Rockford, IL). Each protein sample (100 g) was electrophoresed though SDS-18% Tris ⅐ HCl polyacrylamide gel (BioRad, Hercules, CA). The resolved proteins were transferred to an Immun-Blot polyvinylidene difluoride membrane (BioRad), blocked with 5% nonfat dry milk in Tris-buffered saline (TBS), and incubated with a mouse monoclonal antibody to HIV Tat (Advanced Biotechnologies, Columbia, MD) 1:4,000 in 2% milk-TBS overnight at 4°C. After four washes in TBS-Tween 20, the membrane was incubated with horseradish peroxidase-linked sheep anti-mouse immunoglobulin G (Amersham, Piscataway, NJ) 1:20,000 in 2% milk-TBS for 30 min. The membrane was washed four more times and incubated with SuperSignal West Femto substrate (Pierce). The membrane was exposed to BioMax film (Kodak, Rochester, NY) for 5 min and developed.
HPLC analysis for antioxidants in heart and quadriceps femoris muscle. GSH and ascorbate (Asc) in heart and quadriceps femoris muscle (WT, ϩ/Ϫ Tathigh; n ϭ 6/cohort; 120 days) were analyzed by HPLC coupled with coulometric electrochemical detection (CoulArray model 5600; ESA, Chelmsford, MA). Sample analysis was done with a 7 ϫ 53-mm C-18 reverse phase (Platinum EPS C18 100A 3 m; Altech Associates, Deerfield, IL) and a mobile phase of 125 mM potassium acetate in 1% acetonitrile at pH of 3.0. The electrode potentials in a four-channel electrode array were set at 100, 270, 620, and 730 mV. Under these conditions, Asc and GSH exhibited retention times of 2.82 and 3.14 min, respectively. Antioxidant concentrations were deter-mined from a 5-l injection and based on a five-point standard curve generated with freshly prepared standards.
Echocardiography. Echocardiographic studies were performed serially in WT and ϩ/Ϫ Tathigh and ϩ/Ϫ TatlowA TGs (90, 240, and 365 days) essentially as described previously (21, 30) . At least three sequential measurements were obtained (n ϭ 3-16 per cohort).
Transmission electron microscopy. Methods were as described previously (30) . Each heart provided ϳ10 samples for embedding. Myocardium was rinsed in cold Ringer solution and postfixed in 1% OsO4 (Sigma, St. Louis, MO) in PBS, pH 7.4. for 2-3 h. After osmication and rinses, tissue was dehydrated with graded ethanols and embedded in resin (38) . Myocardial samples were sectioned (100 nm), stained with uranyl acetate, and examined on a JEOL-JEM-100CX electron microscope. Photomicrographs were enlarged to 8 ϫ 10-in. prints and reviewed for the presence of structurally abnormal mitochondria (as done previously; Ref. 30) .
Statistical analysis. Groups were compared by ANOVA as previously described (30) . Significance was established with P Ͻ 0.05.
RESULTS
Tissue specificity of RNA expression. A transgenic mouse was created that expressed HIV Tat in the heart and that developed a pathophysiological cardiovascular phenotype. Northern analysis of total RNA from different tissues from ϩ/Ϫ Tat high TGs revealed significant levels of Tat RNA only in the heart and the absence of signal in other tissues (Fig. 1A) . Northern analysis of RNA extracted from ϩ/Ϫ Tat lowA revealed similar tissue specificity (data not shown).
TAT mRNA expression. Northern analysis of Tat mRNA showed strong signal in blots from ϩ/Ϫ Tat high and ϩ/ϩ Tat high TGs (Fig. 1B) (Fig. 1D) . Tat signal was absent in myocardial extract from WT littermates (Fig.  1D) . Samples from representative 60-day ϩ/Ϫ Tat high and ϩ/Ϫ Tat lowA mice revealed strong signals in the myocardial extracts (Fig. 1D ). Purified Tat served as an external standard (Fig. 1D) .
mRNA markers of ventricular remodeling. Characteristic molecular changes of cardiac remodeling were found in RNA extracts from hearts of 180d ϩ/Ϫ Tat high mice ( Fig. 2A) . GAPDH was the internal control. By quantitative analysis of the radioactive signals, a twofold increase in steady-state abundance of ANF mRNA was found in ventricular samples from ϩ/Ϫ Tat high TGs versus WTs (Fig. 2B) . Signal for SERCA2 was unchanged. In cardiac ventricular RNA extracts from ϩ/Ϫ Tat high TGs (60 days), steady-state abundance of ANF was unchanged compared with that of WT littermates (data not shown). Steady-state abundance of antioxidants in heart and quadriceps femoris muscle. Steady-state abundance of GSH and Asc was determined in heart and quadriceps femoris samples from 120-day ϩ/Ϫ Tat high and WT littermates (Table 1) . GSH abundance (nmol/mg protein) in heart samples from ϩ/Ϫ Tat high mice was 2.9 Ϯ 0.4 (means Ϯ SE) compared with 4.7 Ϯ 0.8 in WT littermates (Table 1 ; P Ͻ 0.05). Steady-state abundance of Asc in the myocardium was unchanged. Similarly, steady-state abundance of GSH and Asc in quadriceps femoris muscle samples from ϩ/Ϫ Tat high mice was unchanged from the respective values in WT littermates (Table 1) . Transmission electron microscopy of heart muscle. Cardiac mitochondrial features were striking and included destruction, enlargement, and loss of cristae in homozygous ϩ/ϩ Tat high TGs at 10 days (Fig. 3) . In contrast, significant but less prominent mitochondrial structural defects (which worsened with increasing age) were found in hemizygous ϩ/Ϫ Tat high TGs. At 60 days, samples from ϩ/Ϫ Tat high TG hearts revealed essentially normal mitochondria. However, at 210-365 days, cardiac mitochondrial damage and enlargement were unambiguous (Fig. 3) . Mitochondria from hearts of WT littermates were essentially normal (Fig. 3,  bottom) . Mitochondria from quadriceps femoris samples were normal in ϩ/Ϫ Tat high mice (data not shown). Echocardiographic data from WT, ϩ/Ϫ Tat high , and ϩ/Ϫ Tat lowA mice. M-mode echocardiograms were performed and evaluated (single observer) on WT, ϩ/Ϫ Tat high , and ϩ/Ϫ Tat lowA mice (90, 240, and 365 days). LV thickening was found in the ϩ/Ϫ Tat high TGs after as little as 90 days. Quantitatively, ϩ/Ϫ Tat high TG hearts showed a 46% increase in LV mass at 90 days (P Ͻ 0.05), 134% increase at 240 days (P Ͻ 0.001), and 96% increase at 365 days (P Ͻ 0.001; Fig. 4A ). Corresponding changes in LV FS were 28% at 90 days, 27% at 240 days, and 19% at 365 days (P Ͻ 0.001 for each comparison to WT littermates; Fig. 4B ). Early in life, ϩ/Ϫ Tat high TG hearts revealed no change in LV mass (30 and 60 days; data not shown). Additionally, at comparable time points up to 365 days, echocardiograms of ϩ/Ϫ Tat lowA TGs showed no change in LV mass (data not shown).
DISCUSSION
A targeted TG with cardiac-specific expression of HIV Tat was created, and a cardiac pathophysiological phenotype resulted. To our knowledge, this is the first time an HIV gene has been selectively expressed transgenically in cardiac myocytes and the first time a cardiac phenotype resulted from its targeted expression.
In the past, nonspecific TG models of AIDS were generated (23, 24) in which various phenotypes were observed. One well-studied TG, the NL4-3⌬ gag/pol (generalized expression of a replication-incompetent HIV construct), exhibited AIDS nephropathy prominently (13) and cardiac dysfunction (30) . Recently, a TG rat was generated (with the same NL4-3⌬ gag/pol Values (in nmol/mg protein) are means Ϯ SE. ϩ/Ϫ Tathigh, high-Tatexpression transgenic mice (TG); WT, wild-type mice; Q. femoris, quadriceps femoris; GSH, glutathione; Asc, ascorbate. * P Ͻ 0.05. construct) with AIDS nephropathy prominently and cardiac injury and repair (36) . Multisystem disease could impact on cardiac function in these models.
In murine TGs with generalized expression of Tat, phenotypic manifestations included skin lesions, liver disease, lymphoid and other malignancies, and hematologic diseases (7-10, 18, 25, 35, 40) . In contrast, our TG lines (operationally defined as ϩ/Ϫ Tat high , ϩ/ϩ Tat high , and ϩ/Ϫ Tat lowA,B ) offer the advantage of targeted Tat expression combined with an organ-specific phenotype. This allows us to monitor for organ dysfunction longitudinally in the living animal and to follow its natural history.
The TG lines ϩ/Ϫ Tat high and ϩ/Ϫ Tat lowA exhibited high and low Tat expression, respectively. ϩ/Ϫ Tat high and ϩ/Ϫ Tat lowA TG pups developed and matured normally, were fertile, exhibited normal litter size, and survived up to 2 years. In contrast, homozygous ϩ/ϩ Tat high pups died prematurely at ϳ14 days. Ultrastructural pathological examination of hearts from ϩ/ϩ Tat high pups euthanized at 10 days (i.e., ϳ4 days before typical death) revealed no gross structural abnormalities or inflammation. However, profound structural changes in cardiac mitochondria were found by transmission electron microscopy in samples from 10-day ϩ/ϩ Tat high pups. Pathophysiological findings in the ϩ/Ϫ Tat high TG followed a logical temporal sequence. Data suggest that from 90 to 210 days, cardiac remodeling occurs. At 60 days, robust Tat mRNA was expressed along with Tat polypeptide. At that time, ANF mRNA changes were absent. As early as 90 days, LV FS and LV mass changes of early cardiac dysfunction were found. At 120 days, GSH depletion was evident. At 180 days, ventricular expression of ANF (a sensitive marker of cardiac dysfunction; Ref. 22 ) was abundant. Transmission electron microscopy mitochondrial changes were unambiguous at 210 days and proceeded to 365 days. Common findings included cristae and matrix disruption, lamellar figures, incomplete fusion, or undivided mitochondria. These changes paralleled echocardiographic changes of CM. These combined structural and functional changes indicate that Tat caused a mitochondrial CM in which a cumulative threshold effect may be observed (41) that resembles the pathophysiology of some other forms of CM.
The pathophysiology of CM in this model suggests that oxidative stress plays a role. In TGs with ubiquitous Tat expression (driven by the ␤-actin promoter), inhibition of glutathione synthase (9) and depletion of GSH occurred in the liver. Decreased GSH occurred selectively in ϩ/Ϫ Tat high TG hearts but not in WT hearts or quadriceps femoris samples from ϩ/Ϫ Tat high TGs. Asc was unchanged in both heart and quadriceps femoris in any cohort. These findings underscore a relationship between Tat, GSH depletion, and the cardiac-targeted TG phenotype. GSH is an important cellular antioxidant that can directly modulate cellular transcriptional events (1) . Additionally, GSH is the only defense available in the mitochondria to metabolize hydrogen peroxide. Thus GSH depletion in this organelle renders cells more susceptible to oxidative stress (16) .
M-mode echocardiograms and their quantitative analysis were used to define cardiac dysfunction with age in ϩ/Ϫ Tat high TGs. At 90 days, In summary, we successfully used the ␣-MyHC promoter to drive HIV Tat gene expression in ventricular cardiac myocytes and created a targeted AIDS TG mouse with cardiac dysfunction and CM. The echocardiographic phenotype began at 90 days and continued throughout life. Features of cardiac dysfunction included cardiomegaly, decreased FS, ventricular expression of ANF (a sensitive marker of cardiac dysfunction), and mitochondrial ultrastructural damage that worsened with age. Homozygote ϩ/ϩ Tat high pups died at ϳ14 days with profound cardiac mitochondrial damage. Selective depletion of cardiac GSH links Tat to oxidative stress in this new murine transgenic model of AIDS CM. Future studies with this model may elucidate pathophysiological mechanisms of CM in AIDS and may suggest therapeutic options for treatment or prevention.
